The aim of this study was to investigate whether a combined global positioning system (GPS)/heart rate (HR) monitoring system is a valuable tool to assess, step by step, the physiological response of HR and its relationship with speed in healthy horses competing in an official show jumping class. Six mares performing a standardised warm-up and jumping course were monitored using a HR/GPS device. Venous blood lactate (BL), assessed before and after exercise, showed a significant increase (P = 0.0004) following the physical effort. One-way analysis of variance (ANOVA) showed significant changes in HR throughout the experimental period. The analysis of HR data recorded during the warm-up jumping stage showed significantly higher HR (P = 0.001) in the recovery period compared to the related jumping phase. Shifting the fence height from 100 cm to 125 cm during the warm-up jumps was also found to cause a significant increase (P = 0.016) in HR. According to these preliminary results, the simultaneous logging of heart rate and speed has the potential to be a reliable and powerful technique for field testing that can help in the monitoring of the horse's response to jumping effort during training and competition.

Download full-text PDF

Source
http://dx.doi.org/10.1556/004.2016.019DOI Listing

Publication Analysis

Top Keywords

combined global
8
global positioning
8
heart rate
8
rate monitoring
8
monitoring system
8
warm-up jumping
8
jumping
5
application combined
4
positioning heart
4
system jumper
4

Similar Publications

Background: The presence of multiple comorbid pathologic features in late-onset dementia has been well documented across cohort studies that incorporate autopsy evaluation. It is likely that such mixed pathology potentially confounds the results of interventional trials that are designed to target a solitary pathophysiologic mechanism in Alzheimer's disease and related dementias (ADRD).

Method: The UK ADRC autopsy database was screened for participants who had previously engaged in therapeutic interventional trials for Alzheimer's disease, vascular cognitive impairment, dementia, and/or ADRD prevention trials from 2005 to the present.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Cognition Therapeutics, Purchase, NY, USA.

Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Merry Life Biomedical Company, Ltd., Tainan City, Taiwan, Taiwan.

Background: Alzheimer's disease (AD) is complex in pathogenesis and related to aging biology, especially in late-onset AD. We identified a novel synthetic curcumin analog TML-6 through the platform of 6 biomarkers of anti-aging, anti-inflammation, and anti-Aβ as the potential AD drug candidate. TML-6 exhibits multi-target effects on AD pathogenesis, including the activation of NrF-2, the regulation of autophagic machinery through mTOR, the inhibition of APP synthesis and reduction of Aβ, the upregulation of ApoE, and the inhibition of microglial activation.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

School of Medicine, Johns Hopkins University, and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.

Background: Agitation is a common and disabling symptom of Alzheimer's dementia (AD). Pharmacological treatments are recommended if agitation is not responsive to psychosocial intervention. Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R- but not S-enantiomer.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

The TT & WF Chao Center for BRAIN and Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.

Background: Global epidemiological studies involving over nine million participants have shown a 35% lower incidence of Alzheimer's Disease (AD) in older cancer survivors compared to those without a history of cancer. This inverse relationship, consistent across recent studies with methodological controls, suggests that cancer itself, rather than cancer treatments, may offer protective factors against AD. This insight opens avenues for novel therapeutic strategies targeting early AD by harnessing cancer-associated protective factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!